Trial Profile

A phase I trial of AGX 1009 for Hepatitis B.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGX 1009 (Primary)
Indications Hepatitis B
Focus Adverse reactions

Most Recent Events

23 Jul 2013 Agenix is poised to submit a new drug clinical trial application (CTA) for AGX-1009 with the China Food and Drug Administration (CFDA), according to a media release.
27 Mar 2013 An Agenix media release states that the company are still on track to submit a new drug clinical trial application in China.
05 Sep 2012 Planned initiation date changed from 1 Dec 2013 to 1 Jun 2014.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com